Eli Lilly and Company (LLY)

The market is throwing a Halloween sale right now that it doesn't need to throw, and that's an opportunity.

These stocks are priced for total imperfection. That's just what you want.

A little bit of luck and a lot of homework can go a long way to make Big Money out of Mad Money. It's buying a Biogen, a Centene, or a Bristol-Myers that could do just that for you.

The aging population is creating a massive tailwind for companies that provide cutting-edge health care.

Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.

Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.

Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.

With prices in a downtrend with a $95 price target, hold off on purchases until prices hold for the drugmaker.

Watch the Russell 2000, housing activity, and mergers and acquisitions.

The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.

The names include a veterinary drug concern plus companies with successful drugs on the market.

The initial public offering of Hansoh Pharmaceutical Group made the Chinese couple Zhong Huijuan and Sun Piaoyang the richest in the nation.

Let's step back and look at the bigger picture through charts and indicators.

I want you to remember Eli Lilly and Johnson & Johnson the next time you are about to dump a stock because of some bits of bad news.

The charts of the maker of recreational vehicles are bearish, while the drugmaker appears to be a buy

Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?

But is a Teva turnaround still coming after the stock's 70% loss in the past five years?

This health care selloff shows the value of diversification to protect our portfolios -- and to go on the offensive and find bargains.

When you see that money pouring out of the market it is going to be looking for a home. The home will most likely want some economic sensitivity.

In this day and age, companies must be 'disruptors' or get left in the dust.

David Tepper's Appaloosa LP renews calls for changes at the top.

If we can advance without China then who the heck knows where we can go with it.

Pets can bring significant profits to companies that cater to this niche market.

Focus on individual stock picking, and take a look at small-caps, as earnings season continues.

The market can still go higher, but the time has come for the slope of price discovery to normalize a bit.

Jim Cramer said that Eli Lilly was the best of the pharmaceutical companies as he looked at the companies reporting earnings this week.

These themes are working despite the turmoil in Washington and slowing global growth.

So far 2019 is proving to be a year where things have a habit of working out right.

Deals that simply were unworkable four months ago because of price are now being done with alacrity.